Terrence C. Kearney - 10 Aug 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Aug 2023
Net transactions value
-$2,224,600
Form type
4
Filing time
14 Aug 2023, 16:09:17 UTC
Previous filing
03 May 2023
Next filing
03 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $1,275,400 +10,000 +153% $127.54 16,536 10 Aug 2023 Direct
transaction VRTX Common Stock Sale $3,500,000 -10,000 -60% $350.00 6,536 10 Aug 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -10,000 -50% $0.000000 10,000 10 Aug 2023 Common Stock 10,000 $127.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.
F2 Fully vested.